BiotechTube

ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Androgenetic Alopecia (AGA)

Conditions

Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female

Trial Timeline

Dec 3, 2025 → Jul 1, 2028

NCT ID
NCT07317544

About ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection

ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection is a phase 1/2 stage product being developed by AbSci for Androgenetic Alopecia (AGA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07317544. Target conditions include Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07317544Phase 1/2Recruiting

Competing Products

12 competing products in Androgenetic Alopecia (AGA)

See all competitors
ProductCompanyStageHype Score
minoxidilJohnson & JohnsonPhase 3
77
Minoxidil + vehicle of 5% Minoxidil topical foamJohnson & JohnsonPhase 2
52
5% Minoxidil Topical Foam + Vehicle Topical FoamJohnson & JohnsonPhase 3
77
Cyproterone Acetate (Androcur, BAY94-8367)BayerPre-clinical
20
Clascoterone 5% solution + Vehicle solutionICON plc.Phase 3
74
Clascoterone 5% solution + Vehicle solutionICON plc.Phase 3
74
VDPHL01VeradermicsPhase 2
47
VDPHL01 QD + Placebo + VDPHL01 BID + PlaceboVeradermicsPhase 3
72
VDPHL01 + PlaceboVeradermicsPhase 2/3
60
VDPHL01 + PlaceboVeradermicsPhase 3
72
MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 WeeksOrganonPhase 3
72
ATI-50002Aclaris TherapeuticsPhase 2
44